Nutritional Concepts

Here's a fascinating area of cancer research that doesn't get nearly enough attention. At very high doses delivered intravenously—150 to 190 times a typical supplement—vitamin C stops behaving like an antioxidant and becomes a prooxidant, generating hydrogen peroxide around tumors. Cancer cells, which carry more reactive iron and operate under higher oxidative stress, appear uniquely vulnerable to this, while normal cells are largely spared.
The early human data is striking. In a randomized phase 2 trial at the University of Iowa, patients with metastatic pancreatic cancer—one of the hardest cancers to treat—who received IV vitamin C alongside chemotherapy showed roughly double the survival of chemo alone (16 months vs. 8), and tolerated treatment so much better they received nearly twice as much of it. The monitoring board stopped enrollment early because the benefit was so clear. Encouraging signals have also appeared in glioblastoma and bladder cancer.
The biggest obstacle now isn't science—it's funding. Vitamin C can't be patented, so there's little commercial incentive to run the large phase 3 trial that would confirm these findings. Until then, this remains a promising but still-investigational therapy.

Here's a finding that challenges the "lower LDL is always better" narrative — and it's one every patient on a statin or aggressive lipid-lowering protocol should know about.

A study published in Cardiovascular Diabetology followed adults with no prior history of type 2 diabetes or cardiovascular disease and tracked who developed diabetes over time. The result: those with the lowest LDL cholesterol levels (under 84 mg/dL) had the highest risk of developing type 2 diabetes. Overall, 13% of participants developed diabetes — but that number jumped to 20% among statin users, compared to just 6% among non-users. The relationship between lower LDL and higher diabetes risk held across the analysis.

This matters because current ACC/American Heart Association guidelines are pushing LDL targets below 70 mg/dL for many patients. That's an aggressive target, and findings like this are a reminder that optimizing one number in isolation can come with trade-offs elsewhere. Comprehensive cardiometabolic assessment — not just LDL — is the standard we apply at Nutritional Concepts.

Most people have heard of uric acid in the context of gout or kidney stones — but there's a much bigger story here that doesn't get nearly enough attention.

A study published in Nutrition Journal tracked uric acid levels across the full cardiometabolic disease progression — from first diagnosis, to developing multiple conditions simultaneously, all the way to mortality. The finding was striking: every 1 mg/dL increase in serum uric acid above the normal range was independently associated with higher risk at every stage of that progression. That makes it one of the more actionable inflammation-linked biomarkers available on a standard blood panel.

This is exactly why uric acid is part of the blood work we review at Nutritional Concepts. It's an inexpensive, underutilized test that can surface cardiometabolic risk years before a diagnosis. If you haven't had yours checked recently — or don't know what your number means — it's worth a conversation.